Medical devices, healthcare technology and the business of care
510(k) clearance · K252951

Genesis Sleep

Neurofield, Inc. · Decision date Dec 31, 2025

FDA DECISIONK252951

What did the FDA decide?

FDA records K252951 as a 510(k) premarket notification, with a decision dated Dec 31, 2025. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Dec 31, 2025

FDA source record

Regulatory record facts

Identifier
K252951
Regulatory pathway
510(k) premarket notification
Product code
QJQ
Decision code
SESE
Decision date
Dec 31, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cranial Electrotherapy Stimulator To Treat Insomnia And/Or Anxiety.

Product code
QJQ
FDA device class
2

FDA decision timeline

  1. K252951 received

    Application receipt date recorded by FDA.

  2. K252951 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neurofield, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Santa Barbara, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records